The objective of this study is to demonstrate whether high-dose plerixafor can effectively mobilize hematopoietic stem cells in patients with sickle cell disease. It will also learn about the safety of this drug in higher doses in these patients. The main questions it aims to answer are:
Does high-dose plerixafor mobilize enough hematopoietic stem cells? What medical problems do participants have when taking high-dose plerixafor?
Participants will:
Undergo transfusion Take high-dose plerixafor Be submitted to stem cell collection by apheresis Visit the clinic 10 days after the procedure Be contacted by the research team 30 days after the procedure.
None
None
Single group
Plerixafor Dose Escalation
DrugPlerixafor will be administered as a single dose of 480 mcg/kg.
CD34⁺ cell count
Proportion of patients who achieve a CD34⁺ cell count \> 5 × 10⁶/kg body weight after HSC collection using plerixafor at a dose of 480 µg/kg
Click on the lead sponsor to view all of their trials.
Hospital Israelita Albert Einstein
Lead sponsor
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
